Allogene Therapeutics Inc. (NASDAQ: ALLO) has announced positive updated findings of Phase 1 UNIVERSAL study of single-dose ALLO-32 in r/r multiple myeloma.
Allogene presents ALLO-32 data during 63rd ASH Meeting
Assistant Attending Physician at Memorial Sloan Kettering Cancer Center in New York, Dr. Sham Mailankody, presented the data in an oral session at the 63rd American Society of Hematology Annual Meeting in Atlanta. The study uses ALLO-647, the company’s anti-CD52 monoclonal antibody, as part of the differentiated lymphodepletion regimen.
Mailankody stated, “UNIVERSAL is the first study of an allogeneic anti-BCMA CAR T to demonstrate safety and substantial efficacy in patients with relapsed-refractory multiple myeloma. Safety, response and durability are on par with the approved autologous CAR T therapy and appear to be superior to other readily available therapies for multiple myeloma. This is especially encouraging given the high percentage of penta-refractory patients enrolled in the study. The data validates the feasibility of ALLO-715 as an allogeneic, on demand CAR T product that may be an option for patients with rapidly progressing disease and limited treatment options.”
ALLO-32 can induce a deep, meaningful response in patients
Allogene EVP Research and Development Rafael Amado said, “We are encouraged by these updated findings from the UNIVERSAL study that show a single dose of an off-the-shelf AlloCAR T product is capable of inducing deep, clinically meaningful responses in patients with r/r multiple myeloma. This proof-of-concept data will form the basis for evaluating anti-BCMA strategies that include consolidated dosing of ALLO-715, ALLO-715 in combination with the gamma secretase inhibitor nirogacestat, and ALLO-605, our next-generation anti-BCMA TurboCAR™, with the goal of achieving even better outcomes for patients with refractory myeloma.”
The company had enrolled 48 patients as of October 14, 2021, cut off with 43 patients assessable for efficacy and safety. The enrolled patients were refractory to past myeloma therapy lines and had a median of five past therapy lines. Around 42% of the patients were penta-refractor which means the disease had become nonresponsive to other available therapies. Because of rapidly progressing disease, five patients were ineligible for treatment.
